Do Not Stop Namenda (Memantine) 10mg Abruptly
You should NOT stop memantine abruptly—it must be tapered gradually over several weeks to avoid potential worsening of cognition, function, and neuropsychiatric symptoms. 1
Recommended Tapering Protocol
The 2020 Canadian Consensus Conference on Dementia provides explicit guidance on how to discontinue memantine safely:
- Reduce the dose by 50% every 4 weeks until you reach the initial starting dose (typically 5 mg/day)
- After 4 weeks at the starting dose, the medication can then be discontinued 1
For a patient on 10 mg/day, this means:
- Week 1-4: Reduce to 5 mg/day
- Week 5-8: Continue 5 mg/day
- Week 9: Discontinue
Why Gradual Tapering Matters
Abrupt discontinuation can cause clinically significant deterioration. The evidence shows:
- Discontinuation syndrome has been documented with memantine, resulting in significant behavioral disturbances and decline beyond the natural disease course 2
- Even when memantine is restarted after abrupt cessation, patients may require additional medications to return to their previous baseline 2
- Gradual tapering allows monitoring for any decline that may be related to stopping the medication, with the option to reinitiate if clinically meaningful worsening occurs 1
When to Consider Discontinuation
Before deciding to stop memantine at all, ensure the patient meets appropriate criteria for deprescribing 1:
Consider discontinuation if:
- Clinically meaningful worsening over past 6 months despite treatment (without other medical causes)
- No benefit ever observed during treatment
- Severe/end-stage dementia with limited life expectancy
- Intolerable side effects (confusion, dizziness, falls)
- Poor medication adherence
Do NOT discontinue if:
- The patient has active psychotic symptoms, agitation, or aggression (unless these worsened with memantine) 1
- Memantine has provided meaningful reduction in neuropsychiatric symptoms 1
Critical Monitoring During Tapering
Watch closely for worsening during the taper period. If you observe clinically meaningful decline in:
- Cognition
- Daily functioning
- Neuropsychiatric symptoms
- Global assessment
Then reinitiate treatment immediately 1
Common Pitfall to Avoid
The most dangerous mistake is abrupt cessation without tapering. The FDA label does not specifically address discontinuation protocols 3, but clinical guidelines and case reports clearly demonstrate that gradual withdrawal is essential to minimize harm 1, 2. The discontinuation syndrome can be distressing for both patients and caregivers and may result in a decline that exceeds what would be expected from disease progression alone.